Dr. Pamela Miel, MD
Claim this profileThe Oncology Institute of Hope and Innovation
Affiliated Hospitals
The Oncology Institute Of Hope And Innovation
The Oncology Institute Of Hope & Innovation - California
Clinical Trials Pamela Miel, MD is currently running
Disitamab Vedotin + Pembrolizumab vs Chemotherapy
for Bladder Cancer
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting
2 awards
Phase 3
AVM0703
for Lymphoma
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
Recruiting
1 award
Phase 1 & 2
6 criteria
More about Pamela Miel, MD
Clinical Trial Related
2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Pamela Miel, MD has experience with
- AVM0703
- Supra-Pharmacologic Dexamethasone Sodium Phosphate
- WGI-0301
- Carboplatin
- Cisplatin
- Disitamab Vedotin
Breakdown of trials Pamela Miel, MD has run
Diffuse Large B-Cell Lymphoma
B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Pamela Miel, MD specialize in?
Pamela Miel, MD focuses on Lymphoma and Diffuse Large B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved treating patients, or patients who are undergoing treatment.
Is Pamela Miel, MD currently recruiting for clinical trials?
Yes, Pamela Miel, MD is currently recruiting for 2 clinical trials in Whittier California. If you're interested in participating, you should apply.
Are there any treatments that Pamela Miel, MD has studied deeply?
Yes, Pamela Miel, MD has studied treatments such as AVM0703, Supra-Pharmacologic Dexamethasone sodium phosphate, WGI-0301.
What is the best way to schedule an appointment with Pamela Miel, MD?
Apply for one of the trials that Pamela Miel, MD is conducting.
What is the office address of Pamela Miel, MD?
The office of Pamela Miel, MD is located at: The Oncology Institute of Hope and Innovation, Whittier, California 90603 United States. This is the address for their practice at the The Oncology Institute of Hope and Innovation.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.